Elderly patients with skin diseases are often accompanied by other diseases and face the problem of polypharmacy, which increases the risk of adverse drug reactions (ADR). In this paper, the problems of polypharmacy for the elderly in dermatology were discussed, and the principles and strategies of medication for the elderly in dermatology were provided, so as to provide reference for the majority of medical workers when prescribing to the elderly patients with skin diseases

Jiaxi Qiao. Medication strategies for the elderly in dermatology. Frontiers in Medical Science Research (2022) Vol. 4, Issue 9: 1-5. https://doi.org/10.25236/FMSR.2022.040901.

[1] WAHLICH J, STEGEMANN S, ORLU-GUL M. Meeting commentary--"medicines for older adults: learning from practice to develop patient centric drug products" [J]. Int J Pharm, 2013, 456(1): 251-7.

[2] MUNIR P, SALLY J, SHAUN M, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients [J]. BMJ (Clinical research ed), 2004, 329(7456).

[3] NASHWA M, SEPEHR S, LISA K-E, et al. What is polypharmacy? A systematic review of definitions [J]. BMC geriatrics, 2017, 17(1).

[4] L M R, JOSEPH H, R H E. Clinical consequences of polypharmacy in elderly [J]. Expert opinion on drug safety, 2014, 13(1).

[5] DORSA M, NAGHAM A, A. M A, et al. Alterations in drug disposition in older adults: a focus on geriatric syndromes [J]. Expert Opinion on Drug Metabolism & Toxicology, 2021, 17(1).

[6] DAVIES E, O'MAHONY M. Adverse drug reactions in special populations - the elderly [J]. British journal of clinical pharmacology, 2015, 80(4): 796-807.

[7] TM A, I K, BV B, et al. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting [J]. Clinical Interventions in Aging, 2014, Volume 9.

[8] ALI A, AZMI A H M, HADZLIANA Z, et al. Prevalence and treatment outcomes of skin infections among elderly population: a retrospective cross-sectional study [J]. The Journal of dermatological treatment, 2020, 32(7).

[9] LIU Wei,YU Dehua,JIN Hua et al. Analysis and Evaluation of Multiple Drug Use among Elderly Patients with Multiple Chronic Conditions in Community [J]. Chinese General Practice, 2020, 23(13): 1592-8.

[10] A G M, K G A, H F N. Polypharmacy in dermatology: analysis of a nationally representative sample of 46,273 dermatology patient visits in the United States from 1995 to 2009 [J]. Skinmed, 2013, 11(5).

[11] DHIRAJ K, ANUPAM D, DEBABRATA B, et al. Dermatoses in the elderly: Clinico-demographic profile of patients attending a tertiary care centre [J]. Indian Journal of Dermatology, 2021, 66(1).

[12] Expert Consensus on Risk Management of Polypharmacy in Elderly Endocrinology and Metabolism Branch of Chinese Association of Geriatric Research,Committee of Clinical Toxicology of Chinese Society of Toxicology [J]. Chinese General Practice, 2018, 21(29): 3533-44.

[13] ROSSELLO X, POCOCK S, JULIAN D. Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care [J]. Journal of the American College of Cardiology, 2015, 66(11): 1273-85.

[14] ENDO J O, WONG J W, NORMAN R A, et al. Geriatric dermatology Part I. Geriatric pharmacology for the dermatologist [J]. Journal of the American Academy of Dermatology, 2013, 68(4).

[15] GIL Y, Y T M B. Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options [J]. Drugs & aging, 2002, 19(11).

[16] MOKOS Z B, JOVIĆ A, ČEOVIĆ R, et al. Therapeutic challenges in the mature patient [J]. Clinics in Dermatology, 2018, 36(2).

[17] LAVAN A H, GALLAGHER P. Predicting risk of adverse drug reactions in older adults [J]. Therapeutic Advances in Drug Safety, 2016, 7(1).

[18] S F T, M M K, BECKY B, et al. Adverse drug events resulting from patient errors in older adults [J]. Journal of the American Geriatrics Society, 2007, 55(2).

[19] VITO D L, MOHAMAD G. An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly [J]. Expert opinion on biological therapy, 2018, 18(8).

[20] LUISA C, ANTONIO D P, ROSARIO P, et al. Small molecule therapy for managing moderate to severe psoriatic arthritis [J]. Expert opinion on pharmacotherapy, 2017, 18(15).

[21] SERGEYENKO A M, ROSENFELD D J, TSOUKAS M M. Chronic immunosuppression in the mature patient [J]. Clinics in Dermatology, 2018, 36(2).

[22] SUSUMU I, MICHIKO I, YOKO F, et al. Assessment of medication adherence and treatment satisfaction in Japanese patients with psoriasis of various severities [J]. The Journal of dermatology, 2018, 45(6).

[23] ILUN T, CHAOCHUN Y, CHIACHENG L E, et al. Psoriasis in the geriatric population: A retrospective study in Asians [J]. The Journal of Dermatology, 2021, 48(6).